Peripheral Vascular Disease (PVD) News 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Shockwave Therapy Shows Benefit in Lower Limb Claudication
(MedPage Today) -- Extracorporeal shockwave therapy may be effective for intermittent lower limb claudication in peripheral artery disease (PAD) patients unable to engage in supervised exercise or who experienced little benefit from that standard... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - April 10, 2024 Category: Cardiology Source Type: news
Roche and Alnylam present positive results from the Phase II KARDIA-2 study of zilebesiran added to standard of care antihypertensives in patients with inadequately controlled hypertension
The KARDIA-2 study met its primary endpoint demonstrating additive, placebo-adjusted systolic blood pressure reductions of up to 12.1 mmHgat month three. These results were statistically significant and clinically meaningfulZilebesiran demonstrated an encouraging safety and tolerability profile when added to standard of care antihypertensives Basel, 7 April 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Alnylam today released detailed results from the Phase II KARDIA-2 study evaluating the efficacy and safety of a single subcutaneous dose of zilebesiran when added to one of three standard of care (SOC) antihypertensives. T...
Source: Roche Investor Update - April 7, 2024 Category: Pharmaceuticals Source Type: news
Liraglutide May Ease Peripheral Artery Disease in T2D Liraglutide May Ease Peripheral Artery Disease in T2D
The drug significantly increased peripheral perfusion over 6 months compared with conventional cardiovascular risk factor treatment.Medscape UK (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - March 19, 2024 Category: Cardiology Tags: Diabetes & Endocrinology Source Type: news
Slowing of Peripheral Artery Disease: Another Liraglutide Benefit?
(MedPage Today) -- Liraglutide (Victoza), a type 2 diabetes drug, may help prevent peripheral artery disease (PAD) progression, the small, open-label STARDUST trial suggested.
Over 6 months, adults with type 2 diabetes on subcutaneous liraglutide... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - March 14, 2024 Category: Cardiology Source Type: news
Roche and Alnylam report positive topline results from the Phase II KARDIA-2 study in people with hypertension, demonstrating clinically significant blood pressure reductions with zilebesiran when added to standard of care
KARDIA-2 study met its primary endpoint, demonstrating clinically significant systolic blood pressure reductions in each treatment arm at month threeZilebesiran added to a standard of care hypertension medication demonstrated an encouraging safety and tolerability profile in adults with mild to moderate uncontrolled hypertension, and results support the potential for twice-yearly dosingRoche and Alnylam have initiated the Phase II KARDIA-3 study in adults with uncontrolled hypertension at high cardiovascular riskKARDIA-2 study results will be presented as a late-breaking abstract in April at the 2024 American College of Ca...
Source: Roche Investor Update - March 5, 2024 Category: Pharmaceuticals Source Type: news
Roche and Alnylam report positive topline results from the Phase II KARDIA-2 study in people with hypertension, demonstrating clinically significant blood pressure reductions with zilebesiran when added to standard of care
KARDIA-2 study met its primary endpoint, demonstrating clinically significant systolic blood pressure reductions in each treatment arm at month threeZilebesiran added to a standard of care hypertension medication demonstrated an encouraging safety and tolerability profile in adults with mild to moderate uncontrolled hypertension, and results support the potential for twice-yearly dosingRoche and Alnylam have initiated the Phase II KARDIA-3 study in adults with uncontrolled hypertension at high cardiovascular riskKARDIA-2 study results will be presented as a late-breaking abstract in April at the 2024 American College of Ca...
Source: Roche Media News - March 5, 2024 Category: Pharmaceuticals Source Type: news
New minimally invasive treatment helps Upstate patients with peripheral artery disease
This approach is effective for patients with long lesions, who have already undergone failed endovascular procedures, or who may be suboptimal candidates for open surgical bypass. (Source: SUNY Upstate Medical)
Source: SUNY Upstate Medical - November 9, 2023 Category: Universities & Medical Training Tags: News Source Type: news
Evident Vascular secures $35M to develop IVUS platform
San Jose, CA-based startup Evident Vascular has secured $35 million in Series A funding from Vensana Capital to develop an AI-enabled intravascular ultrasound (IVUS) platform. The platform's development will focus on applications for the treatment of peripheral vascular disease, a slow and progressive circulation disorder that affects the legs and feet."Robust clinical trial data supporting utilization in both coronary and peripheral interventions are fueling future market growth," the company said. (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - October 18, 2023 Category: Radiology Authors: AuntMinnie.com staff writers Tags: Industry News Source Type: news
Home-Based Exercise Benefits Patients With PAD Home-Based Exercise Benefits Patients With PAD
New evidence shows home-based exercise could be a first-line therapy for walking limitations in peripheral artery disease.Medscape Medical News (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - October 6, 2023 Category: Orthopaedics Tags: Cardiology News Source Type: news
Roche and Alnylam report positive topline results from Phase 2 study KARDIA-1 of zilebesiran, an investigational RNAi therapeutic in development to treat hypertension in patients at high risk of cardiovascular disease
Zilebesiran met primary endpoint demonstrating greater than 15 mmHg reduction of systolic blood pressure at three months of treatment compared to placeboStudy met key secondary endpoints showing consistent and sustained reductions of systolic blood pressure at six monthsZilebesiran demonstrated an encouraging safety and tolerability profile in adult patients with mild-to-moderate hypertensionFull study results to be presented at an upcoming scientific conferenceBasel, 7 September 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Alnylam announced today that the Phase 2 study KARDIA-1 of zilebesiran, an investigational RNAi the...
Source: Roche Media News - September 7, 2023 Category: Pharmaceuticals Source Type: news
Roche and Alnylam report positive topline results from Phase 2 study KARDIA-1 of zilebesiran, an investigational RNAi therapeutic in development to treat hypertension in patients at high risk of cardiovascular disease
Zilebesiran met primary endpoint demonstrating greater than 15 mmHg reduction of systolic blood pressure at three months of treatment compared to placeboStudy met key secondary endpoints showing consistent and sustained reductions of systolic blood pressure at six monthsZilebesiran demonstrated an encouraging safety and tolerability profile in adult patients with mild-to-moderate hypertensionFull study results to be presented at an upcoming scientific conferenceBasel, 7 September 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Alnylam announced today that the Phase 2 study KARDIA-1 of zilebesiran, an investigational RNAi the...
Source: Roche Investor Update - September 7, 2023 Category: Pharmaceuticals Source Type: news
Who Is to Blame for the Rampant Overtreatment of Peripheral Artery Disease?
(MedPage Today) -- The recent New York Times article highlighting inappropriate treatment patterns among patients with peripheral artery disease (PAD) has made a serious but much needed impact on patients and physicians alike. The article is complemented... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - August 13, 2023 Category: Cardiology Source Type: news
PAD Procedure Overuse: Field in Peril or'A Few Bad Apples'? PAD Procedure Overuse: Field in Peril or'A Few Bad Apples'?
Two investigative stories highlighted peripheral artery disease treatment that left many patients with an amputation, the outcome they were told they could avoid.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - July 28, 2023 Category: Cardiology Tags: Cardiology News Source Type: news
Roche enters partnership with Alnylam to co-develop and co-commercialise RNAi therapeutic zilebesiran to treat hypertension in patients with high cardiovascular risk
Partnership combines Roche ’s proven track record of successfully developing and launching innovative medicines worldwide withAlnylam ’s leadership in RNAi therapeuticsZilebesiran, a Phase 2 RNAi therapeutic, has best-in-disease potential for patients with hypertension at high risk of cardiovascular morbidity and mortality, by robustly and durably lowering blood pressureHypertension, the leading cause of cardiovascular disease, affects more than 1.2 billion adults worldwide. While several therapies exist, a significant unmet need, especially for high risk patients, remains.1Basel, 24 July 2023 - Roche (SIX: RO, ROG; OT...
Source: Roche Media News - July 24, 2023 Category: Pharmaceuticals Source Type: news
Roche enters partnership with Alnylam to co-develop and co-commercialise RNAi therapeutic zilebesiran to treat hypertension in patients with high cardiovascular risk
Partnership combines Roche ’s proven track record of successfully developing and launching innovative medicines worldwide withAlnylam ’s leadership in RNAi therapeuticsZilebesiran, a Phase 2 RNAi therapeutic, has best-in-disease potential for patients with hypertension at high risk of cardiovascular morbidity and mortality, by robustly and durably lowering blood pressureHypertension, the leading cause of cardiovascular disease, affects more than 1.2 billion adults worldwide. While several therapies exist, a significant unmet need, especially for high risk patients, remains.1Basel, 24 July 2023 - Roche (SIX: RO, ROG; OT...
Source: Roche Investor Update - July 24, 2023 Category: Pharmaceuticals Source Type: news
